Medtronic Inc MDT

$94.23 +1.22 (1.31%)

Valuation

Market cap
118,972,624,000
Revenue TTM
$36,364,000,000
Net income TTM
$4,800,000,000
PE ratio
16.07
Forward PE
15.38
Profit margin
13.20%
Debt to equity
0.55

Trading

Volume
49,863,600
Avg volume
17,028,840
Day's range
$92.16 – $94.72
Shares out
1,279,138,000
Stochastic %K
95%
Beta
0.55
Analysts
Sell
Price target
$102.36

Price

Company profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, an...

Show more

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.

Industry
Medical Devices
Sector
Healthcare
Phone
353 1 438 1700
Website
https://www.medtronic.com
Address
Building Two, Parkmore Business Park West, Galway, Ireland

Latest news

Stocktwits

ImRonBurgundy Oct 14, 9:22 PM
$MDT New position here at 93.17.
0 replies
Albino_Trader123 Oct 14, 5:41 AM
$MDT Slower name: nice 50ma reclaim gap supported with volume increase
0 replies
dustlesspuma Oct 14, 2:31 AM
🟢 $MDT 90C Dec 18 💰 $105,000 premium 💵 $5.8/contract 📊 2.7x Vol/OI 📍 Spot $91.99 💰 Large premium | 🚨 Repeat sweep 🌊 Dark Flow | Options Flow
0 replies
inelegantinvest Oct 12, 11:28 PM
$MDT $MMED MiniMed exchange offer preliminary results: • 298.0M MDT shares tendered • 55.0M expected to be accepted • 18.3% preliminary proration • 4.5939 MMED shares per accepted MDT share • Qualifying odd lots exempt 93.3M shares were tendered through guaranteed-delivery procedures, so the final proration could change. Final results expected October 14. https://www.stockspinoffs.com/2026/10/12/medtronic-minimed-exchange-proration-18-percent/
0 replies
Oruveek70 Oct 12, 4:10 PM
$MDT 'The corporate separation of Medtronic's diabetes unit into an independent, publicly traded entity--MiniMed Group. Inc (listed on the Nasdaq: MMED)--was structured precisely to unlock maximum shareholder value.' https://news.medtronic.com/2026-10-07-Medtronic-Announces-Final-Exchange-Ratio-of-4-5939-in-Split-Off-of-MiniMed-Group,-Inc
0 replies
zzddamz Oct 12, 1:59 PM
$MDT why all the sudden MDT is too attractive? Is today deciding the shares between mdt and minimed?
0 replies
OnlyFibs Oct 11, 11:36 PM
$MDT | BULLISH 🐂 ⭐ Setup Quality Grade: B+ 📌 Grade Justification: • Profitability: Top 15th Percentile ($37.5B TTM revenue, $5.3B net income, 65.0% gross margin, 3.27% dividend yield). • Revenue Growth: Top 30th Percentile (+9.9% reported / +6.6% organic Q4 sales growth; $5.40–$5.50 FY27 EPS guide). • Options Flow: Short-Term Call Sweeps ($88.4K sweep on Oct 16 $90C + $30.3K sweep on Oct 16 $90C at the ask). • Technical Setup: B+ Grad (1W ascending channel holding $88.00–$89.50 spot above primary volume profile shelf). 🏢 Profile: World’s largest standalone medical device titan ($112B+ market cap) advancing cardiovascular, surgical, and neuroscience tech 📉 Setup: 1W ascending channel support holding $88.00–$89.50 spot directly on volume shelf support! 🔎 Options Flow: Oct 16 $90C (1.8% OTM) ($88.4K sweep at ask) 💸. 🎯 Levels: • Bulls: Hold $87.50 & claim $92.00 ➡️ Targets: $95.50 / $102.00 / $112.00+ 🚀 • Bears: Break under $85.00 support. 🛑 #hovdid
0 replies
sSwSs Oct 9, 2:33 PM
$MDT — Medtronic's strategic advancements, including platform development and a significant spin-off, were central to recent analyses, alongside technical indicators suggesting a bearish trend. Upside noted: Year-over-year quarterly revenue growth was 13.7%. Year-over-year quarterly earnings growth was 40.7%. Dividend yield of 3.28%. Current ratio of 2.067. Risk noted: Current price is below both the 50-day SMA and the 200-day SMA. RSI is below the neutral 50 level. MACD is below zero, indicating bearish momentum. Recent analyses examined Medtronic's strategic initiatives, including the advancement of its Altaviva and Symplicity Spyral platforms and the spin-off of its MiniMed division. The company's significant investment in robotics and its commitment to serving a large patient base were also noted. Technical indicators, such as SMAs and RSI, suggested a bearish short-to-medium term trend, despite some short-term upward momentum.
0 replies